Intertek is the industry leader with over 42,000 people in 1,000 locations in over 100 countries. Whether your business is local or global, we can ensure your products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world.
Protein Structure Characterisation and Conformation
Protein structure characterisation and conformation services in line with EMA, FDA and ICH guidelines which include protein sequencing, peptide mapping, post-translational modification studies and higher order structure studies
Protein structure characterisation is fundamental to biologic development and ongoing quality control, in terms of identification and product homology. Proteins have complex structures which must be characterised from the primary sequence of amino acids, through to higher order structure. In accordance with the ICH Q6B Guidelines, it is important to perform an overall assessment of structural heterogeneity to demonstrate protein identity and consistency of manufactured batches. The tests selected can be qualitative in nature, but should be highly specific for the drug product and should be based on unique aspects of the molecular structure.
Our protein scientists have a great deal of expertise in delivering analytical programs that are strategically designed to optimise the data required to determine or confirm identity, explore patterns of heterogeneity and demonstrate consistency in quality of the drug substance.
We provide extensive protein characterization during the development phase and, where necessary, following significant process changes. To support your submission, we can provide data to Good Laboratory Practice (GLP) or Good Manufacturing Practice (GMP), as appropriate, with comparison against the most suitable reference standard, if available. Our laboratories are equipped with a broad technology base and our strengths in mass spectrometry (Orbitrap and QToF) analysis, in particular, allow the ability to provide high-resolution, accurate-mass (HRAM) data.
Our Total Quality Assurance expertise makes Intertek the perfect partner to expedite your protein structural characterisation programs to meet your development, submission or ongoing processing needs.
We apply a number of approaches to determine the Amino Acid sequence normally involving high-resolution accurate-mass spectrometry (Orbitrap, QToF) coupled with U(H)PLC technology and Amino Acid Analysis methods. Proteins or peptides are normally digested with various enzymes in order to produce suitable peptide fragments for LC-MS/MS. The mass of the peptides and the fragmentation data is used to determine the Amino Acid sequence. These studies are often accompanied by Amino Acid Analysis for the quantitative distribution of the amino acids present in the protein.
Intertek conduct selective fragmentation of the selected protein into discrete peptides by enzyme or chemical digestion followed by high-resolution mass spectrometry (Orbitrap, QToF) analysis. Peptide map methods can then be validated as UPLC-UV (MS) and used routinely for batch release or stability studies.
Confirmation of the amino-terminal (N-terminal) and carboxy-terminal (C-terminal) amino acids is performed by MALDI-MS and high resolution mass spectrometry (Orbitrap, QToF) for product identification and to establish homogeneity, where understanding the type and extent of modifications at either termini, is a fundamental aspect of product quality control.
Where cysteine residues are present in the molecule, our scientists perform a qualitative / semi-quantitative assessment of the position and extent of expected and mismatched disulphide bridges by high resolution mass spectrometry (Orbitrap, QToF) and colorimetric tests for free sulfhydryl groups.
The higher-order structure is examined using far and near-UV circular dichroism (CD), nuclear magnetic resonance (NMR), infrared spectroscopy (FTIR), intrinsic fluorescence studies or ultraviolet-visible (UV-vis, second derivative) spectroscopy. Our biophysical characterisation suite of technologies also includes protein aggregation studies through dynamic light scattering, SEC with multi-angle laser light scattering (MALS), sedimentation velocity analytical ultracentrifugation (SV-AUC) and Differential Scanning Calorimetry (DSC).
Glycosylation studies are product specific, however, these typically include determination of the levels of neutral and amino monosaccharides as well as sialic acids, assessment of glycoform distribution and glycan structure elucidation. Multiple technologies are applied to these studies including selective enzymatic cleavage and MALDI-TOF mass spectrometry, HPAEC-PAD, HILIC-FLD or CE-LIF, to provide the level of structural information required.
For antibody drug conjugates (ADCs) our scientists determine the position of attachment of the toxin to the linker and subsequently protein, also known as the sites of conjugation. This is typically achieved using high resolution mass spectrometry (Orbitrap, QToF) following enzymatic digestion. The same logic methods can also be applied to establishing the position of PEGylation and other conjugated forms.